Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI and state-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable.
GeneCentric Diagnostics is engaged in the development and commercialization of molecular diagnostic tests aimed at assisting oncologists and patients in cancer treatment. The company has established two primary platform technologies: The Lung Subtype Platform (LSP), which classifies lung cancer patients into specific subtypes to guide therapeutic choices, and the Hypoxia Signature, designed to identify patients likely to benefit from anti-angiogenesis therapies. The LSP has been licensed to Laboratory Corporation of America Holdings and is available as HistoPlusSM: Lung Cancer through its Integrated Oncology division. GeneCentric's innovative partnership model facilitates the translation of significant cancer research into diagnostics that are clinically adopted by pathologists and clinicians. Incorporated in 2011 and located in Durham, North Carolina, GeneCentric aims to enhance treatment outcomes by enabling more precise targeting of therapeutic compounds based on tumor biology.
StrideBio, Inc. creates and develops adeno-associated viral (AAV) vector technologies and therapeutics that enables gene addition, gene silencing, and gene editing modalities for rare diseases. The company develops a proprietary platform by combining structural information with accelerated evolution to create novel AAV capsids that can evade neutralizing antibodies. The company was founded in 2015 and is based in Durham, North Carolina.
NoviSci improve the health and well-being of people through principled data science.
Atsena Therapeutics is a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness.
Altis Biosystems is a biotechnology company developing research tools for the pharma and biotech industries. The company has developed a patent-pending stem cell technology recreating the human intestinal epithelium for compound screening and microbiome research. Their organ on a chip product produces a layer of human or animal intestinal stem and differentiated cells, either of the small or large intestine. These cells can be used for disease modeling, precision medicine, microbiome research, and compound screening.
Atsena Therapeutics is a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness.
410 Medical is a healthcare company based in Durham, North Carolina, founded in 2013. It specializes in developing a rapid infuser device designed to assist critically ill patients who require volume resuscitation. This innovative solution enables healthcare providers to quickly deliver fluids, including blood and other essential components, thereby enhancing the speed and efficiency of care for patients facing life-threatening conditions like sepsis and shock. The device allows for fast setup and minimizes provider fatigue, enabling a single healthcare provider to manage multiple patient care issues simultaneously. It is particularly beneficial in pre-hospital settings and emergency departments, where timely intervention is crucial and resources may be constrained.
WalletFi offers a proprietary platform that identifies recurring charges, subscriptions, and CoF payments, and allows users and financial institutions to transfer those payments to a new card in case of re-issuance. WalletFi reduces customer churn for banks and financial institutions while also increasing customer engagement and reinforcing top-of-wallet status.
Ribometrix is a platform therapeutics company that discovers small molecule drugs that target functional 3D RNA structures to treat human diseases.
Our scientific offices are located in the newly renovated Biolabs Space in Durham, with offices in Chapel Hill and Boston.
StrideBio, Inc. creates and develops adeno-associated viral (AAV) vector technologies and therapeutics that enables gene addition, gene silencing, and gene editing modalities for rare diseases. The company develops a proprietary platform by combining structural information with accelerated evolution to create novel AAV capsids that can evade neutralizing antibodies. The company was founded in 2015 and is based in Durham, North Carolina.
Clinipace Inc. is a clinical research organization that provides integrated clinical research services to pharmaceutical, biotechnology, and medical device companies in the United States and globally. Founded in 2003 and headquartered in Morrisville, North Carolina, Clinipace specializes in various therapeutic areas, including oncology, nephrology, gastroenterology, cardiology, diabetes, and respiratory diseases. The company offers a comprehensive range of services such as biostatistics, clinical monitoring, patient recruitment, regulatory affairs, and legal representation. With additional offices in Boulder, Colorado, and international locations in Argentina, Brazil, Europe, and the Asia Pacific, Clinipace emphasizes collaboration and flexibility in its approach, distinguishing itself from traditional clinical research organizations.
Ribometrix is a platform therapeutics company that discovers small molecule drugs that target functional 3D RNA structures to treat human diseases.
Our scientific offices are located in the newly renovated Biolabs Space in Durham, with offices in Chapel Hill and Boston.
StrideBio, Inc. creates and develops adeno-associated viral (AAV) vector technologies and therapeutics that enables gene addition, gene silencing, and gene editing modalities for rare diseases. The company develops a proprietary platform by combining structural information with accelerated evolution to create novel AAV capsids that can evade neutralizing antibodies. The company was founded in 2015 and is based in Durham, North Carolina.
Mati Inc. is a company based in Durham, North Carolina, that specializes in the production and sale of energy drinks. Founded in 2012, it offers a unique energy drink brewed from plant-based ingredients, fruit juice concentrates, and water. The flagship product, MATI, is designed to provide a healthier alternative for active and health-conscious consumers seeking to enhance their everyday performance. Mati Inc. distributes its products through various channels, including wholesalers, retail outlets, and online platforms, primarily serving customers in North Carolina and surrounding counties. As of April 2020, Mati Inc. operates as a subsidiary of NOBL Beverages.
NeuroTronik
Series B in 2017
NeuroTronik, spun out of medical technology incubator Synecor, is developing a medical device that could take the place of drugs currently used to heart failure. Read more about the company's technology,
Bivarus, Inc. develops a cloud-based analytics platform for measuring continuous quality improvement (CQI) and the patient experience to hospital-based outpatient service lines, community-based clinics, and group practices through patient-centered insights. Its platform enables customers to gain insights into the drivers impacting the patient experience, buying behavior, and provider performance, as well as to improve patient care and service operations. Bivarus, Inc. was founded in 2010 and is based in Durham, North Carolina. As of January 16, 2018, Bivarus, Inc. operates as a subsidiary of Press Ganey Holdings, Inc.
Boragen Inc. is a biotechnology company based in Durham, North Carolina, that specializes in designing and developing multifunctional small molecule boron solutions for applications in crop protection, animal health, and human health. Founded in 2015, the company focuses on creating next-generation fungicides through its synthetic chemistry platforms, which aim to promote sustainable farming practices. Boragen's product pipeline includes BAG8, a boron-based multisite fungicide, and BN2266, which targets mRNA processing as a crop protection fungicide. Additionally, the company is developing a dual-function nematicide-fungicide designed for root protection and endo-parasiticides that address resistance challenges. Through its innovative approach, Boragen seeks to enhance agricultural efficiency while minimizing chemical usage.
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapeutics for cancer treatment. Founded in 2008, the company is headquartered in Research Triangle Park, North Carolina. G1 Therapeutics is advancing several investigational therapies, including trilaciclib, an intravenous cyclin-dependent kinase (CDK) 4/6 inhibitor, currently undergoing Phase 1b/2 trials for extensive-stage small cell lung cancer and Phase 2 trials for first-line small cell lung cancer and metastatic triple-negative breast cancer. The company is also developing lerociclib, an oral CDK4/6 inhibitor, which is in Phase 1b/2a trials for breast cancer and Phase 1b trials for non-small cell lung cancer. Additionally, G1 Therapeutics is progressing rintodestrant, an oral selective estrogen receptor degrader, currently in Phase I/2 trials. The company has partnered with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment in locally advanced breast cancer. G1 Therapeutics aims to improve treatment outcomes for cancer patients through its innovative therapeutic approaches.
Bivarus, Inc. develops a cloud-based analytics platform for measuring continuous quality improvement (CQI) and the patient experience to hospital-based outpatient service lines, community-based clinics, and group practices through patient-centered insights. Its platform enables customers to gain insights into the drivers impacting the patient experience, buying behavior, and provider performance, as well as to improve patient care and service operations. Bivarus, Inc. was founded in 2010 and is based in Durham, North Carolina. As of January 16, 2018, Bivarus, Inc. operates as a subsidiary of Press Ganey Holdings, Inc.
Medfusion, Inc. operates a patient engagement portal aimed at enhancing healthcare services for providers and patients in the United States and internationally. The platform facilitates communication through various clinical, administrative, and financial services, including billing solutions such as online bill pay and payment plans, as well as secure patient messaging and prescription renewal requests. Medfusion also offers front desk solutions like appointment requests and patient registration, along with mobile applications that empower patients to access their health data. Additional services include EHR/PM integration and Practice Intelligence, which provides insights into patient communication traffic. Founded in 1996 and based in Cary, North Carolina, Medfusion originally focused on medical website development for healthcare clients, evolving to meet the specific needs of the healthcare sector.
Spyryx Biosciences is a biopharmaceutical company based in Durham, North Carolina, specializing in the development of inhaled peptide therapeutics aimed at treating obstructive lung diseases, specifically cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD). Founded in 2013 by Dr. Robert Tarran, the company emerged from his discovery of a novel mechanism by which the lungs regulate surface fluid. This mechanism is impaired in CF patients due to genetic mutations, leading to dehydration, mucus buildup, and subsequent lung damage. Spyryx's therapeutic approach targets this underlying dysfunction, showing promising results in preclinical studies by significantly improving survival in animal models of CF. Importantly, the treatment is designed to function independently of the specific genetic mutations responsible for CF, offering potential benefits to a broader patient population. Additionally, the company is exploring the relevance of this fluid regulation mechanism in COPD, a condition characterized by chronic bronchitis and emphysema, as part of its commitment to addressing multiple obstructive lung diseases.
Contego Medical, Inc. develops emboli protection devices that are used for the treatment of cardiovascular and endovascular diseases. It offers angioplasty balloons and stent delivery catheters, such as coronary stent systems, carotid post-dilation balloons, and renal artery stent systems with integrated embolic protection devices for enabling carotid, renal, SVG, and coronary interventions. Contego Medical, Inc. was formerly known as Contego Medical, LLC. The company was founded in 2005 and is based in Raleigh, North Carolina with an additional office in Curitiba, Brazil.
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapeutics for cancer treatment. Founded in 2008, the company is headquartered in Research Triangle Park, North Carolina. G1 Therapeutics is advancing several investigational therapies, including trilaciclib, an intravenous cyclin-dependent kinase (CDK) 4/6 inhibitor, currently undergoing Phase 1b/2 trials for extensive-stage small cell lung cancer and Phase 2 trials for first-line small cell lung cancer and metastatic triple-negative breast cancer. The company is also developing lerociclib, an oral CDK4/6 inhibitor, which is in Phase 1b/2a trials for breast cancer and Phase 1b trials for non-small cell lung cancer. Additionally, G1 Therapeutics is progressing rintodestrant, an oral selective estrogen receptor degrader, currently in Phase I/2 trials. The company has partnered with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment in locally advanced breast cancer. G1 Therapeutics aims to improve treatment outcomes for cancer patients through its innovative therapeutic approaches.
Private Equity Round in 2015
Clinipace Inc. is a clinical research organization that provides integrated clinical research services to pharmaceutical, biotechnology, and medical device companies in the United States and globally. Founded in 2003 and headquartered in Morrisville, North Carolina, Clinipace specializes in various therapeutic areas, including oncology, nephrology, gastroenterology, cardiology, diabetes, and respiratory diseases. The company offers a comprehensive range of services such as biostatistics, clinical monitoring, patient recruitment, regulatory affairs, and legal representation. With additional offices in Boulder, Colorado, and international locations in Argentina, Brazil, Europe, and the Asia Pacific, Clinipace emphasizes collaboration and flexibility in its approach, distinguishing itself from traditional clinical research organizations.
Viamet Pharmaceuticals discovers and develops "best-in-class" inhibitors of validated metalloenzymes via an innovative and proprietary metal-binding approach, their Metallophileâ„¢ Technology. Viamet's disruptive Metallophileâ„¢ technology is based on their world-class expertise in bioinorganic chemistry and metalloenzymes and allows them to identify validated targets with high therapeutic and commercial potential; leverage existing metalloenzyme inhibitors as the basis for Viamet's best-in-class analogs; and rapidly and cost-effectively generate best-in-class, patentable, small molecule compounds by optimizing the metal-binding component of existing inhibitors.
Clinverse is a technology company solely focused on the financial management of clinical trials and associated payments in over 140 currencies. Our flagship product, ClinPay, is a secure on-line eClinical Trial Payment Network that dramatically reduces time spent on the investigator payment process with significant increases in clinical trial productivity. ClinPay links sponsors to investigators in a payment and reporting system that reduces study start-up time, makes possible timely and accurate payments, provides transparency and auditing records, and simplifies compliance.
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapeutics for cancer treatment. Founded in 2008, the company is headquartered in Research Triangle Park, North Carolina. G1 Therapeutics is advancing several investigational therapies, including trilaciclib, an intravenous cyclin-dependent kinase (CDK) 4/6 inhibitor, currently undergoing Phase 1b/2 trials for extensive-stage small cell lung cancer and Phase 2 trials for first-line small cell lung cancer and metastatic triple-negative breast cancer. The company is also developing lerociclib, an oral CDK4/6 inhibitor, which is in Phase 1b/2a trials for breast cancer and Phase 1b trials for non-small cell lung cancer. Additionally, G1 Therapeutics is progressing rintodestrant, an oral selective estrogen receptor degrader, currently in Phase I/2 trials. The company has partnered with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment in locally advanced breast cancer. G1 Therapeutics aims to improve treatment outcomes for cancer patients through its innovative therapeutic approaches.
GeneCentric Diagnostics is engaged in the development and commercialization of molecular diagnostic tests aimed at assisting oncologists and patients in cancer treatment. The company has established two primary platform technologies: The Lung Subtype Platform (LSP), which classifies lung cancer patients into specific subtypes to guide therapeutic choices, and the Hypoxia Signature, designed to identify patients likely to benefit from anti-angiogenesis therapies. The LSP has been licensed to Laboratory Corporation of America Holdings and is available as HistoPlusSM: Lung Cancer through its Integrated Oncology division. GeneCentric's innovative partnership model facilitates the translation of significant cancer research into diagnostics that are clinically adopted by pathologists and clinicians. Incorporated in 2011 and located in Durham, North Carolina, GeneCentric aims to enhance treatment outcomes by enabling more precise targeting of therapeutic compounds based on tumor biology.
Clinipace Inc. is a clinical research organization that provides integrated clinical research services to pharmaceutical, biotechnology, and medical device companies in the United States and globally. Founded in 2003 and headquartered in Morrisville, North Carolina, Clinipace specializes in various therapeutic areas, including oncology, nephrology, gastroenterology, cardiology, diabetes, and respiratory diseases. The company offers a comprehensive range of services such as biostatistics, clinical monitoring, patient recruitment, regulatory affairs, and legal representation. With additional offices in Boulder, Colorado, and international locations in Argentina, Brazil, Europe, and the Asia Pacific, Clinipace emphasizes collaboration and flexibility in its approach, distinguishing itself from traditional clinical research organizations.
Viamet Pharmaceuticals discovers and develops "best-in-class" inhibitors of validated metalloenzymes via an innovative and proprietary metal-binding approach, their Metallophileâ„¢ Technology. Viamet's disruptive Metallophileâ„¢ technology is based on their world-class expertise in bioinorganic chemistry and metalloenzymes and allows them to identify validated targets with high therapeutic and commercial potential; leverage existing metalloenzyme inhibitors as the basis for Viamet's best-in-class analogs; and rapidly and cost-effectively generate best-in-class, patentable, small molecule compounds by optimizing the metal-binding component of existing inhibitors.
ArtusLabs is developing and deploying Web 2.0 enabled software platforms that enable groups of scientists, and thereby individual scientists, to deliver significantly better (and more) business value to their shareholders, faster. ArtusLabs was founded by the same proven team that formed Synthematix, the award winning organization that pioneered the Enterprise Electronic Lab Notebook marketplace. This leadership and development team has extensive expertise in processing, mining and managing complex scientific data and information generated from research activities. With a wealth of experience and very close relationships with scientists around the globe, the team at ArtusLabs continues to build the best collaborative customer experience and technologies for researchers -- hands down.
Clinipace Inc. is a clinical research organization that provides integrated clinical research services to pharmaceutical, biotechnology, and medical device companies in the United States and globally. Founded in 2003 and headquartered in Morrisville, North Carolina, Clinipace specializes in various therapeutic areas, including oncology, nephrology, gastroenterology, cardiology, diabetes, and respiratory diseases. The company offers a comprehensive range of services such as biostatistics, clinical monitoring, patient recruitment, regulatory affairs, and legal representation. With additional offices in Boulder, Colorado, and international locations in Argentina, Brazil, Europe, and the Asia Pacific, Clinipace emphasizes collaboration and flexibility in its approach, distinguishing itself from traditional clinical research organizations.
Viamet Pharmaceuticals discovers and develops "best-in-class" inhibitors of validated metalloenzymes via an innovative and proprietary metal-binding approach, their Metallophileâ„¢ Technology. Viamet's disruptive Metallophileâ„¢ technology is based on their world-class expertise in bioinorganic chemistry and metalloenzymes and allows them to identify validated targets with high therapeutic and commercial potential; leverage existing metalloenzyme inhibitors as the basis for Viamet's best-in-class analogs; and rapidly and cost-effectively generate best-in-class, patentable, small molecule compounds by optimizing the metal-binding component of existing inhibitors.
Empliant, Inc., located in Chapel Hill, N.C., provides web-native, employee self-reliant data collection solutions. Online benefits enrollment reduces administrative costs, increases employee satisfaction, and enhances operational efficiency. Their technology applications include on-line benefits enrollment and administration and personalized employee benefits statements. They also deliver a fully searchable content management knowledgebase for benefit plan information, company policies, or management practices. Their Software as a Service (SaaS) solution eliminates up front costs and enables employers to provide employees with self-service capabilities for pennies a day per employee. Empliant offers small to medium-sized enterprises (SME) the rich functionality found in expensive applications without the consulting costs, long implementation period, and reliance on customer support and product maintenance.